Loading...

ALMS ALUMIS INC Company Mergers 8-K Filing

LMS

LMS

ALUMIS INC

(ALMS)

2025 8-K

Clinical Trial Update

Financial Results Announced

Stock Offering Announced

New Drug Results

Financial Results Update

Investor Presentation Update

Financial Results Announced

Merger of Equals

Merger of Equals

Merger of Equals

Financial Statements

Merger Agreement

Collaboration Agreement

Financial Results

Clinical Trial Results

Merger Confirmation

Merger Agreement

External Links:

Alumis Inc. has entered into a merger agreement with ACELYRIN, where ACELYRIN will merge into Alumis, with ACELYRIN shareholders receiving 0.4274 shares of Alumis stock for each share they own, and Alumis currently has approximately $289 million in cash and equivalents as of December 31, 2024.

AI Assistant

ALUMIS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.